Bruker (NASDAQ:BRKR) Rating Increased to Strong-Buy at Zacks Research

Bruker (NASDAQ:BRKR) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other research analysts also recently issued reports on BRKR. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Leerink Partners upped their target price on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Citigroup decreased their target price on shares of Bruker from $60.00 to $53.00 and set a “neutral” rating for the company in a research note on Wednesday. JPMorgan Chase & Co. boosted their price target on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. Finally, Wall Street Zen raised Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Bruker has an average rating of “Moderate Buy” and an average target price of $56.64.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $52.47 on Tuesday. The stock has a market cap of $7.99 billion, a P/E ratio of -74.96, a P/E/G ratio of 1.61 and a beta of 1.28. Bruker has a twelve month low of $28.53 and a twelve month high of $65.30. The stock has a 50 day moving average of $58.67 and a two-hundred day moving average of $46.73. The company has a current ratio of 1.85, a quick ratio of 0.72 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. During the same period last year, the firm posted $0.32 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts forecast that Bruker will post 2.12 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BRKR. Orbis Allan Gray Ltd raised its stake in shares of Bruker by 5.4% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock worth $702,256,000 after buying an additional 761,258 shares during the last quarter. State Street Corp lifted its stake in shares of Bruker by 2.5% during the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock worth $180,700,000 after purchasing an additional 91,706 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. Sculptor Capital LP boosted its holdings in shares of Bruker by 9.0% during the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock worth $118,112,000 after purchasing an additional 270,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after purchasing an additional 2,289,269 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.